<scp>NCRI</scp> phase <scp>II</scp> study of <scp>CHOP</scp> in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome
Toby A. Eyre(Churchill Hospital), Anna Schuh(National Institute for Health Research), George Follows(Cambridge University Hospitals NHS Foundation Trust), Adrian Bloor(The Christie NHS Foundation Trust), Maité Cabes(National Health Service), Lucy Boyle(University of Oxford), Basile Stamatopoulos(Université Libre de Bruxelles), Peter Hillmen(Leeds Teaching Hospitals NHS Trust), Sharon Love(Nuffield Orthopaedic Centre), Ruth Clifford(Churchill Hospital), Elizabeth J. Soilleux(University of Cambridge), John G. Gribben(Queen Mary University of London), Helen O. McCarthy(Queen's University Belfast), Christopher P. Fox(Nottingham University Hospitals NHS Trust), Stephen Devereux, Graham P. Collins(Churchill Hospital), J. A. H. Murray(Cardiff University), Tim Littlewood(Churchill Hospital), Andrew Wotherspoon(Université Libre de Bruxelles), Andrew R. Pettitt(University of Liverpool), Chris S.R Hatton(Churchill Hospital), Corran Roberts(Nuffield Orthopaedic Centre)
Cited by 66
Related Papers
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k